A Phase I, Multipart, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7497372 Following Intravitreal Administration in Participants With Diabetic Macular Edema (Part 1 Non-Randomized, Open-Label, Multiple Ascending Dose; Part 2 Randomized, Double-Masked)
Latest Information Update: 20 Jun 2025
At a glance
- Drugs RO 7497372 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Acronyms Pregonda
- Sponsors Genentech
Most Recent Events
- 04 Mar 2025 New trial record